OBJECTIVE: To investigate the clinical efficacy of @entity2518 photodynamic therapy (ALA-PDT) for cervical @entity281 . METHODS: In this prospective study, a total of 76 @entity1 with persistent cervical @entity281 were randomly divided into two groups. The treatment group (39 @entity1 ) received three treatments of ALA-PDT at two-week intervals. The control group (37 @entity1 ) received no treatment. All @entity1 were followed up for 9 months. Hybrid Capture HPV DNA Assay and ThinPrep cytology test (TCT) were performed for both groups. @entity1 with abnormal TCT results received colposcopic biopsy before treatment and during follow-ups. RESULTS: HR-HPV remission rates were 64.10% (25/39) in the treatment group and 24.32% (9/37) in the control group at 3 month follow-up. Complete remission rates were 76.92% (30/39) and 32.40% (12/37), respectively, in the two groups at 9 month follow-up. There was a statistically significant difference between the two groups (P <0.01). Conversion rates of abnormal TCT results were 81.81% (9/11) in the treatment group and 12.50% (1/8) in the control group at 3 months, and 90.90% (10/11) and 25.00% (2/8), respectively, at 9 months. Five of six @entity1 with @entity8046     in the treatment group and no @entity1 in the control group achieved complete response at 9 months. There was a statistically significant difference between the two groups (P <0.01). CONCLUSION: Topical ALA-PDT is an effective, safe and well tolerated treatment for cervical @entity281 .

Topical Photodynamic Therapy with XXXX for Cervical High-risk HPV Infection.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity281 :: ('MESH:D007239', 'Disease') :: ['HR-HPV infection', 'high-risk HPV (HR-HPV) infection'] @entity2518 :: ('CHEBI:17549', 'Chemical') :: ['5-aminolevulinic acid'] @entity8046 :: ('57026', 'Gene') :: ['CIN']
@entity2518 :: (CHEBI:17549,Chemical) :: ['5-Aminolevulinic Acid']
